Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM0YZC6)

Drug Name
Fulvestrant Drug Info
Synonyms
Faslodex; AstraZeneca brand of fulvestrant; Fulvestrant [USAN]; Ici 182780; ZD 182780; ZM 182780; Faslodex (TN); ZD-182780; ZD-9238; ZM-182780; Faslodex(ICI 182,780); Faslodex, ICI 182780, Fulvestrant; Fulvestrant (JAN/USAN/INN); (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; ICI
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
104741
ChEBI ID
CHEMBL1358
CAS Number
CAS 129453-61-8
TTD Drug ID
D0JO7Y
INTEDE Drug ID
DR0756

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Valine, leucine and isoleucine degradation 2.14 0.00e+0 42/48 (87.5%) HMGCS1;ALDH6A1;PCCB;...
PPAR signaling pathway 2.10 0.00e+0 66/74 (89.19%) FABP4;HMGCS1;CD36;...
Oxidative phosphorylation 2.05 0.00e+0 93/133 (69.92%) COX5B;NDUFA3;PPA2;...
Glycine, serine and threonine metabolism 2.00 2.45e-3 31/40 (77.5%) BPGM;MAOB;PHGDH;...
Propanoate metabolism 1.99 1.96e-3 30/34 (88.24%) ALDH6A1;PCCB;MMUT;...
Tryptophan metabolism 1.89 1.47e-2 35/42 (83.33%) AOC1;KYAT3;CAT;...
Non-alcoholic fatty liver disease 1.87 1.40e-2 126/155 (81.29%) LEPR;COX5B;NDUFA3;...
Butanoate metabolism 1.87 1.23e-2 23/28 (82.14%) HMGCS1;BDH2;BDH1;...
Synthesis and degradation of ketone bodies 1.86 1.20e-2 9/10 (90%) HMGCS1;BDH2;BDH1;...
Fatty acid degradation 1.86 1.08e-2 40/43 (93.02%) CPT1A;ALDH7A1;ECHS1;...
Peroxisome 1.84 1.07e-2 72/82 (87.8%) CAT;IDH1;GSTK1;...
Other glycan degradation 1.72 3.68e-2 13/18 (72.22%) MAN2B2;NEU1;MAN2C1;...
Protein digestion and absorption -1.72 4.89e-2 78/103 (75.73%) COL8A2;CPB2;FXYD2;...
Type I diabetes mellitus -1.74 4.67e-2 38/43 (88.37%) CD80;HLA-DPB1;CD86;...
DNA replication -1.81 2.73e-2 34/36 (94.44%) RNASEH1;MCM6;POLD1;...
Allograft rejection -1.88 1.43e-2 32/38 (84.21%) CD80;HLA-DPB1;CD86;...
Systemic lupus erythematosus -1.89 1.28e-2 45/135 (33.33%) CD80;FCGR2A;HLA-DPB1;...
Autoimmune thyroid disease -1.90 1.36e-2 46/53 (86.79%) FAS;HLA-DPA1;HLA-A;...
Proteasome -1.91 1.53e-2 44/46 (95.65%) PSMD13;PSMB3;PSMC4;...
Asthma -1.97 1.02e-2 25/31 (80.65%) EPX;HLA-DPA1;FCER1A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 20uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.66uM - 10uM XH
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 2H, 6H, 24H, XH
NCI-H508 CVCL_1561 Homo sapiens 0.66uM - 10uM XH
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H, XH
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 6.66uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H, XH
NCI-H1975 CVCL_1511 Homo sapiens 0.66uM - 10uM XH
NCI-H1975 CVCL_1511 Homo sapiens 0.66uM - 10uM XH
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 0.66uM - 10uM XH
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 0.66uM - 10uM XH
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SU-DHL-4 CVCL_0539 Homo sapiens 0.66uM - 10uM XH
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HL-60 CVCL_0002 Homo sapiens 0.08uM - 10uM 2H, 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H, XH
VCaP CVCL_2235 Homo sapiens - 20uM 6H, 24H, 48H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H, XH
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H